Smoldering Multiple Myeloma
"Smoldering Multiple Myeloma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An asymptomatic and slow-growing PLASMA CELL dyscrasia characterized by presence of MYELOMA PROTEINS and clonal bone marrow plasma cells without end-organ damage (e.g., renal impairment). It is distinguished from MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE by a much higher risk of progression to symptomatic MULTIPLE MYELOMA.
| Descriptor ID |
D000075122
|
| MeSH Number(s) |
C04.834.794 C15.378.147.542.820 C15.378.147.780.838 C20.683.460.820 C20.683.780.838
|
| Concept/Terms |
Smoldering Multiple Myeloma- Smoldering Multiple Myeloma
- Multiple Myeloma, Smoldering
- Smoldering Multiple Myelomas
- Smoldering Myeloma
- Myeloma, Smoldering
- Smoldering Myelomas
- Asymptomatic Multiple Myeloma
- Asymptomatic Multiple Myelomas
- Multiple Myeloma, Asymptomatic
- Multiple Myelomas, Asymptomatic
|
Below are MeSH descriptors whose meaning is more general than "Smoldering Multiple Myeloma".
Below are MeSH descriptors whose meaning is more specific than "Smoldering Multiple Myeloma".
This graph shows the total number of publications written about "Smoldering Multiple Myeloma" by people in this website by year, and whether "Smoldering Multiple Myeloma" was a major or minor topic of these publications.
Below are the most recent publications written about "Smoldering Multiple Myeloma" by people in Profiles.
-
Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell. 2023 06 12; 41(6):1032-1047.e4.
-
The Insider: Impact of the Gut Microbiota on Cancer Immunity and Response to Therapies in Multiple Myeloma. Front Immunol. 2022; 13:845422.
-
Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials. Br J Haematol. 2022 06; 197(6):e86-e88.
-
The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt. Leuk Lymphoma. 2021 11; 62(11):2793-2795.
-
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nat Commun. 2021 03 25; 12(1):1861.
-
Persistent challenges with treating multiple myeloma early. Blood. 2021 01 28; 137(4):456-458.
-
Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy. Adv Ther. 2021 02; 38(2):1328-1341.
-
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia. 2020 07; 34(7):1840-1852.
-
Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders. Best Pract Res Clin Haematol. 2020 03; 33(1):101148.
-
Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat Med. 2018 12; 24(12):1867-1876.